What is Biostage, Inc. (BSTG) stock price today?

Biostage, Inc. (BSTG) is currently trading at $4.03, up 0.75% today.

What is BSTG P/E ratio?

Biostage, Inc.'s P/E ratio is -9.83. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BSTG return on equity (ROE)?

Biostage, Inc.'s return on equity (ROE) is -786.49%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Biostage, Inc.'s market cap?

Biostage, Inc. has a market capitalization of $57.82M.

OTC · Biotechnology

Biostage, Inc. (BSTG) Stock

$4.03 +0.75% OTC: BSTG Healthcare

Valuation

Metric	Value
Price	$4.03
Market Cap	$57.82M
P/E Ratio	-9.83
P/B Ratio	770.11
P/S Ratio	0.00
EPS (TTM)	$-0.42
52-Week High	$9.00
52-Week Low	$3.65
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-786.49%
ROA	-378.81%
ROCE	-800.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	1.88
Current Ratio	0.53

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-9.0M	$-6.0M	$-9.0M	$-8.0M	$-8.0M
Net Profit	$-8.0M	$-6.0M	$-9.0M	$-8.0M	$-7.0M
EPS	$-0.74	$-1.09	$-0.67	$-0.52	$-0.42
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$2.0M	$2.0M	$3.0M	$4.0M	$3.0M
Total Liabilities	$5.0M	$1.0M	$1.0M	$1.0M	$2.0M
Cash	$1.0M	$1.0M	$0	$2.0M	$1.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Assessing Boustead Singapore (SGX:F9D) Valuation After Earnings Surge And New Aerospace Facility Investment Simply Wall St. · May 25, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-3.0M	$-5.0M	$-7.0M	$-5.0M	$-4.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$3.0M	$5.0M	$6.0M	$7.0M	$3.0M
Net Cash Flow	$0	$0	$-1.0M	$2.0M	$-1.0M
Free Cash Flow	$-3.0M	$-5.0M	$-7.0M	$-5.0M	$-4.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.94
EV / EBITDA	543.19
FCF Yield	-6.93%
Quick Ratio	0.52
Interest Coverage	-3868.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ETXPFE-therapeutics Plc	$0.13	+0.00%	-4.71	$75.96M	0.00%
GDNSFGoodness Growth Holdings, Inc.	$0.45	—	-4.52	$61.05M	0.00%
HRPMFHerantis Pharma Oyj	$3.51	+0.00%	-6.09	$59.47M	0.00%
KDEVFKarolinska Development AB (publ)	$0.26	+0.00%	-0.34	$68.85M	0.00%
MCIOFMCI Onehealth Technologies Inc.	$0.55	-1.10%	-1.31	$54.04M	0.00%

About Biostage, Inc.

Biostage, Inc. is a biotechnology enterprise dedicated to developing medical products aimed at curing patients suffering from cancers, injuries, and congenital defects within the gastrointestinal system and respiratory pathways. A primary focus for the company is the advancement of its Biostage Esophageal Implant, specifically designed to address esophageal cancer. Founded in 2009, the organization was formerly known as Harvard Apparatus Regenerative Technology, Inc. before rebranding as Biostage, Inc. in March 2016. Its corporate headquarters are located in Holliston, Massachusetts.

Biostage, Inc. is headquartered in US.

Biostage, Inc. (BSTG) stock trades at $4.03 with a market capitalization of $57.82M. The stock is valued at a price-to-earnings (P/E) ratio of -9.83, price-to-book of 770.11, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.65 and $9.00, and currently trades 55.2% below its 52-week high.

On profitability, Biostage, Inc. generates a return on equity (ROE) of -786.49%, return on capital employed of -800.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: biostage.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides